Traditional Chinese Medicine for Acute Myocardial Infarction in Western Medicine Hospitals in China.
Spatz, ES
Wang, Y
Beckman, AL
Wu, X
Lu, Y
Du, X
Li, J
Xu, X
Davidson, PM
Masoudi, FA
Spertus, JA
Krumholz, HM
Jiang, L
- Publisher:
- LIPPINCOTT WILLIAMS & WILKINS
- Publication Type:
- Journal Article
- Citation:
- Circ Cardiovasc Qual Outcomes, 2018, 11, (3), pp. e004190
- Issue Date:
- 2018-03
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Spatz, ES | |
dc.contributor.author | Wang, Y | |
dc.contributor.author | Beckman, AL | |
dc.contributor.author | Wu, X | |
dc.contributor.author | Lu, Y | |
dc.contributor.author | Du, X | |
dc.contributor.author | Li, J | |
dc.contributor.author | Xu, X | |
dc.contributor.author | Davidson, PM | |
dc.contributor.author | Masoudi, FA | |
dc.contributor.author | Spertus, JA | |
dc.contributor.author | Krumholz, HM | |
dc.contributor.author | Jiang, L | |
dc.date.accessioned | 2022-09-10T22:15:54Z | |
dc.date.available | 2018-02-15 | |
dc.date.available | 2022-09-10T22:15:54Z | |
dc.date.issued | 2018-03 | |
dc.identifier.citation | Circ Cardiovasc Qual Outcomes, 2018, 11, (3), pp. e004190 | |
dc.identifier.issn | 1941-7713 | |
dc.identifier.issn | 1941-7705 | |
dc.identifier.uri | http://hdl.handle.net/10453/161623 | |
dc.description.abstract | BACKGROUND: Amid national efforts to improve the quality of care for people with cardiovascular disease in China, the use of traditional Chinese medicine (TCM) is increasing, yet little is known about its use in the early management of acute myocardial infarction (AMI). METHODS AND RESULTS: We aimed to examine intravenous use of TCM within the first 24 hours of hospitalization (early IV TCM) for AMI. Data come from the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction, restricted to a large, representative sample of Western medicine hospitals throughout China (n=162). We conducted a chart review of randomly sampled patients with AMI in 2001, 2006, and 2011, comparing early intravenous TCM use across years, predictors of any early intravenous TCM use, and association with in-hospital bleeding and mortality. From 2001 to 2011, early intravenous TCM use increased (2001: 38.2% versus 2006: 49.1% versus 2011: 56.1%; P<0.01). Nearly all (99%) hospitals used early intravenous TCM. Salvia miltiorrhiza was most commonly prescribed, used in one third (35.5%) of all patients admitted with AMI. Patients receiving any early intravenous TCM, compared with those who did not, were similar in age and sex and had fewer cardiovascular risk factors. In multivariable hierarchical models, admission to a secondary (versus tertiary) hospital was most strongly associated with early intravenous TCM use (odds ratio: 2.85; 95% confidence interval: 1.98-4.11). Hospital-level factors accounted for 55% of the variance (adjusted median odds ratio: 2.84). In exploratory analyses, there were no significant associations between early intravenous TCM and in-hospital bleeding or mortality. CONCLUSIONS: Early intravenous TCM use for AMI in China is increasing despite the lack of evidence of their benefit or harm. There is an urgent need to define the effects of these medications because they have become a staple of treatment in the world's most populous country. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01624883. | |
dc.format | ||
dc.language | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
dc.relation.ispartof | Circ Cardiovasc Qual Outcomes | |
dc.relation.isbasedon | 10.1161/CIRCOUTCOMES.117.004190 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 1102 Cardiorespiratory Medicine and Haematology, 1117 Public Health and Health Services | |
dc.subject.classification | Cardiovascular System & Hematology | |
dc.subject.mesh | Administration, Intravenous | |
dc.subject.mesh | Aged | |
dc.subject.mesh | China | |
dc.subject.mesh | Drugs, Chinese Herbal | |
dc.subject.mesh | Female | |
dc.subject.mesh | Health Status | |
dc.subject.mesh | Hemorrhage | |
dc.subject.mesh | Hospital Mortality | |
dc.subject.mesh | Hospitals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Medicine, Chinese Traditional | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Myocardial Infarction | |
dc.subject.mesh | Patient Safety | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Risk Assessment | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Myocardial Infarction | |
dc.subject.mesh | Hemorrhage | |
dc.subject.mesh | Drugs, Chinese Herbal | |
dc.subject.mesh | Treatment Outcome | |
dc.subject.mesh | Medicine, Chinese Traditional | |
dc.subject.mesh | Hospital Mortality | |
dc.subject.mesh | Risk Assessment | |
dc.subject.mesh | Risk Factors | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Health Status | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Hospitals | |
dc.subject.mesh | China | |
dc.subject.mesh | Female | |
dc.subject.mesh | Male | |
dc.subject.mesh | Patient Safety | |
dc.subject.mesh | Administration, Intravenous | |
dc.title | Traditional Chinese Medicine for Acute Myocardial Infarction in Western Medicine Hospitals in China. | |
dc.type | Journal Article | |
utslib.citation.volume | 11 | |
utslib.location.activity | United States | |
utslib.for | 1102 Cardiorespiratory Medicine and Haematology | |
utslib.for | 1117 Public Health and Health Services | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2022-09-10T22:15:52Z | |
pubs.issue | 3 | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
utslib.citation.issue | 3 |
Abstract:
BACKGROUND: Amid national efforts to improve the quality of care for people with cardiovascular disease in China, the use of traditional Chinese medicine (TCM) is increasing, yet little is known about its use in the early management of acute myocardial infarction (AMI). METHODS AND RESULTS: We aimed to examine intravenous use of TCM within the first 24 hours of hospitalization (early IV TCM) for AMI. Data come from the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction, restricted to a large, representative sample of Western medicine hospitals throughout China (n=162). We conducted a chart review of randomly sampled patients with AMI in 2001, 2006, and 2011, comparing early intravenous TCM use across years, predictors of any early intravenous TCM use, and association with in-hospital bleeding and mortality. From 2001 to 2011, early intravenous TCM use increased (2001: 38.2% versus 2006: 49.1% versus 2011: 56.1%; P<0.01). Nearly all (99%) hospitals used early intravenous TCM. Salvia miltiorrhiza was most commonly prescribed, used in one third (35.5%) of all patients admitted with AMI. Patients receiving any early intravenous TCM, compared with those who did not, were similar in age and sex and had fewer cardiovascular risk factors. In multivariable hierarchical models, admission to a secondary (versus tertiary) hospital was most strongly associated with early intravenous TCM use (odds ratio: 2.85; 95% confidence interval: 1.98-4.11). Hospital-level factors accounted for 55% of the variance (adjusted median odds ratio: 2.84). In exploratory analyses, there were no significant associations between early intravenous TCM and in-hospital bleeding or mortality. CONCLUSIONS: Early intravenous TCM use for AMI in China is increasing despite the lack of evidence of their benefit or harm. There is an urgent need to define the effects of these medications because they have become a staple of treatment in the world's most populous country. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01624883.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph